OR WAIT null SECS
ChromaDex International has announced the initiation of what the firm calls a “first-of-its-kind” Phase 1 clinical study.
ChromaDex International (Los Angeles, CA) has announced the initiation of what the firm calls a “first-of-its-kind” Phase 1 clinical study. The study, sponsored by the University of Florida, in collaboration with the National Institute of Aging, will assess the potential of branded nicotinamide riboside (NR), Niagen, for enhancing the effects of exercise therapy in older adults with hypertension. The randomized, double-blind study will include 74 hypertensive adults as measured by changes in arterial stiffness, blood pressure and walking performance. It was initiated as part of the ChromaDex External Research Program (CERP), where ChromaDex supplies its NR and placebo at no cost to research institutions worldwide.
“This clinical trial will provide valuable information on the potential of NR supplementation to enhance the benefits of exercise in older populations with hypertension. Published data suggest NR may support cardiovascular health with further study, specifically through improvements in blood pressure (BP) and aortic stiffness. However, older hypertensive adults have yet to be explored in a clinical study,” said primary investigator Robert Mankowski, PhD, Department of Aging and Geriatric Research, the University of Florida, in a press release.